GST case remanded, exposing Nectar Lifesciences to potential ₹95.56 crore demands
As filed · Nectar Lifesciences Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
RegulatoryDeterioratingNotablemateriality 68 out of 100
What happened
FactThe Punjab and Haryana High Court remanded Nectar Lifesciences’ GST dispute to the Appellate Authority for fresh consideration on September 24, 2026. If the matter is reconsidered adversely, the company says it may face a ₹89.32 crore demand plus interest and penalties, and a separate ₹6.24 crore demand; it may appeal to the Tribunal if required.
Why it matters
CapitSignal interpretationLitigation creates a contingent liability that is not in reported profit until it crystallises.
Scale
- 5.7% of FY25 revenue
₹95.56 Cr stated in the filing against ₹1,673.07 Cr revenue (FY25, standalone)
Source: financial_facts · exchange_table
Watch next
Fact- Amount claimed against the company
- Whether a provision has been made
- Next hearing or order date
Evidence
How CapitSignal classified this
- Reasoning:
- The remand reopens a substantial GST dispute after the Appellate Authority had dropped the ₹89.32 crore balance demand. The final liability remains unascertainable, but an adverse reconsideration could create exposure to the stated demands, interest and penalties.
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 75%